Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck

Kübler, Alexander C.; Haase, Thomas; Staff, Christian; Kahle, Birgit; Rheinwald, Markus; Mühling, Joachim

doi:10.1002/(sici)1096-9101(1999)25:1<60::aid-lsm8>3.0.co;2-x

Cited by 104 publications

(75 citation statements)

References 31 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the field of oncology, PDT is primarily used for the treatment of superficially localised tumours (Dougherty et al, 1998). In this context, the area illuminated is accessible, and treatment is associated with minimal toxicity, favourable tumour response and a good cosmetic outcome (Kubler et al, 1999). Photodynamic therapy has also been investigated for the treatment of deep-seated or disseminated malignancies (Biel, 1998); unfortunately, acute damage to surrounding normal tissue and treatment-related toxicity is often observed as a consequence of poor photosensitiser selectivity, and difficulties directing the light source to the tumour mass (Nseyo et al, 1998).…”

mentioning

confidence: 99%

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

et al. 2005

View full text Add to dashboard Cite

A promising approach to increase the specificity of photosensitisers used in photodynamic therapy has been through conjugation to monoclonal antibodies (MAb) directed against tumour-associated antigens. Many of the conjugations performed to date have relied on the activated ester method, which can lead to impure conjugate preparations and antibody crosslinking. Here, we report the development of photosensitiser -MAb conjugates utilising two porphyrin isothiocyanates. The presence of a single reactive isothiocyanate allowed facile conjugation to MAb FSP 77 and 17.1A directed against internalising antigens, and MAb 35A7 that binds to a non-internalising antigen. The photosensitiser -MAb conjugates substituted with 1 -3 mol of photosensitiser were characterised in vitro. No appreciable loss of immunoreactivity was observed and binding specificity was comparable to that of the unconjugated MAb. Substitution with photosensitiser had a minimal effect on antibody biodistribution in vivo for the majority of the conjugates, although a decreased serum half-life was observed using a cationic photosensitiser at the higher loading ratios. Tumour-to-normal tissue ratios as high as 33.5 were observed using MAb 35A7 conjugates. The internalising conjugate showed a higher level of phototoxicity as compared with the non-internalising reagent, using a cell line engineered to express both target antigens. These data demonstrate the applicability of the isothiocyanate group for the development of high-quality conjugates, and the use of internalising MAb to significantly increase the photodynamic efficiency of conjugates during photoimmunotherapy.

show abstract

mentioning

confidence: 99%

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Today, there are several indications and various techniques to use PDT in the head and neck [8,11,21]. The low morbidity and functional disturbances that result from PDT offer many advantages in the treatment of recurrent cancer in particular.…”

Section: Fig 2 Récidive D'un Carcinome éPidermoïde Du Voile Du Palamentioning

confidence: 79%

“…The photosensitizer is usually administrated intravenously several hours prior to illumination [10]. During the time interval between systemic photosensitizer injection and illumination, a concentration ratio between the tumour and surrounding normal tissue occurs [11]. At the time when this ratio is optimum, illumination by a non thermal light of the appropriate wavelength activates the photosensitizer.…”

mentioning

confidence: 99%

Photodynamic therapy as salvage treatment for recurrent head and neck cancer

Gangloff

Phulpin

Cortese

et al. 2012

Med Buccale Chir Buccale

View full text Add to dashboard Cite

-Head and neck cancers often lead to disfiguration or functional impairments after treatment. Local recurrence occurs in around 60% of cases and most of them can not be retreated. Photodynamic therapy (PDT) can be an alternative treatment. In a serie of 10 patients with recurrent squamous cell carcinoma of the head and neck that have failed prior therapies and are unsuitable for conventional curative therapy, PDT treatment has been used. Eight patients have shown complete cicatrisation. Seven patients were cured after the follow up period up to 53 months. Three patients died (one outside etiology). Quality of life was considered as very much for 6 out of 10 patients, quite a bit for 1 patient, a little for 2 patients and not at all for 1 patient. Clinical benefit was evaluated as very much for 6 patients out of 10, quite a bit for 2 patients, a little for 1 patient and not at all for 1 patient. PDT can be proposed to patients with head and neck cancer in palliative situation. It could be a therapeutic solution for selected cases with good outcomes. PDT offers patients a unique chance of remission and increased life expectancy compared with palliative treatments.Résumé -La thérapie photodynamique comme traitement de sauvetage pour les récidives des cancers des voies aéro-digestives supérieures. Les cancers de la tête et du cou conduisent souvent à des séquelles esthétiques ou fonctionnelles majeures après traitement. Des récidives locales sont observées dans environ 60 % des cas et la majorité ne peut pas être retraitée à nouveau. La thérapie photodynamique (PDT) peut être une possibilité de prise en charge alternative. Dans une série de 10 patients présentant une récidive d'un carcinome épidermoïde des voies aéro-digestives supérieures qui n'est plus accessible à traitement curatif conventionnel, la PDT a été utilisée. Huit patients ont montré une cicatrisation complète. Sept patients étaient considérés comme guéris après une période de surveillance allant jusqu'à 53 mois. Trois patients sont décédés (dont un d'une cause extérieure au contexte carcinologique). La qualité de vie a été considérée comme très bonne pour 6 patients sur 10, bonne pour 1 patient, moyenne pour 2 patients et mauvaise pour 1 patient. La PDT est une option thérapeutique qui peut être proposée aux patients atteints de cancers des voies aéro-digestives supérieures et placés en situation de prise en charge palliative. Cela pourrait être une possibilité de prise en charge pour des patients bien sélectionnés qui permettrait d'obtenir de bons résultats. La PDT a offert à ces patients une chance unique de rémission de la maladie et a amélioré indéniablement le taux de survie par rapport à la prise en charge palliative qui était la seule alternative.Key words: head and neck cancer / photodynamic therapy / salvage therapy / photosensitizers / squamous cell carcinoma

show abstract

“…There were 14 small prospective studies (comprising 297 patients) which evaluated the response of SCCs to photodynamic therapy [619][620][621][622][623][624][625][626][627][628][629][630][631][632] (see Appendix 13). Three studies separated SCCs according to level or depth of invasion 619,622,625 and one was a non-randomised two-arm comparison of topical photodynamic therapy either with or without a 5% glycolic acid penetration enhancer.…”

Section: Photodynamic Therapymentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck

Cited by 104 publications

References 31 publications

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

Photodynamic therapy as salvage treatment for recurrent head and neck cancer

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About